NEWS
Agenus mortgages some vaccine royalties for $115M in R&D cash
Agenus ($AGEN) is trading away future royalties on a GlaxoSmithKline…
Bristol-Myers’ latest PD-1 win could pave the path to earlier use
Bristol Myers-Squibb ($BMY), a leader among companies at work…
GlaxoSmithKline takes another big swing at cancer drug R&D
Contrary to a common misperception in the industry, GlaxoSmithKline…
Juno and AstraZeneca pair two hot immunotherapies in new cancer study
Juno Therapeutics ($JUNO) and AstraZeneca ($AZN) are joining…
Virtual biotechs a hit with investors and, increasingly, buyers
Biotech venture capitalists have increasingly embraced the virtual…
Big Pharma-backed Dutch immuno-oncology player eyes €100M Nasdaq IPO
A Dutch immuno-oncology player that has received venture funding…
Personal cancer vaccine research ‘exciting’ say experts
Tailor-made cancer vaccines that target unique genetic errors…
Novartis tackles immuno-oncology with a $750M Aduro deal for new R&D group
Novartis ($NVS), a leader among companies using the immune system…